<qa>  What is the name of the study that patients who have received ABT-888 within 3 weeks- Patients who have had chemotherapy or radiotherapy within 3 weeks 6 weeks for nitrosoureas or mitomycin C prior to entering the study or those who have not recovered to baseline or are not at stable grade 2 from adverse events due to agents administered more than 3 weeks earlier; patients who have received immunotherapy or radioimmunotherapy within 3 months, unless disease has progressed since treatment; patients who have been administered ABT-888 as part of a single or limited dosing study, such as a phase 0 study, will not be excluded from participating in this study solely because of receiving prior ABT-888 